Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:31:32.492Z.
Calculation as of: 2026-10-06T13:31:32.492Z.
Quote observation: 2026-10-06T13:30:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4936500bc1589ca9a686c77de910b68cd28581e4c5f82a550ef1f7d6df46dce9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Evogene Ltd.
Market Cap
$3.39M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Evogene Ltd. (EVGN) | $3.39M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.36M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.34M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.98M | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.18M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.29M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
